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Introduction
Psoriasis is a chronic recurrent skin disease of still not
fully elucidated etiology, observed in both sexes [1-4].
Literature data point out at strong genetic component,
however the mode of inheritance is still unclear and
varies in different types of the disease [3]. In 70% of
monozygotic twins, psoriasis develops concomitantly.
Probability of psoriasis occurrence reaches for 70%
when both parents are affected in comparison to 1-4%
for the general human population [4-6]. The risk of pso-
riasis development is higher when the father is affected
or is a psoriasis susceptibility gene carrier. This phe-
nomenon is called "genomic imprinting" [5,7]. 
Some researchers pointed out at autosomal dominant
mode of inheritance with 60% of penetrance [4,5,8],
while others multigenic and multifactorial mode of
inheritance with environmental factors such as mechan-
ical traumas, dietary factors, infections, psychological
stressors, drugs (including lithium, antimalarials, beta-
blockers, NSAiD, salicylates) [4,5,9-14].   
Furthermore, significant positive correlation
between human leukocyte antigens (HLA) and psoria-
sis has been observed [15]  including class I HLA i.e.
HLA-B13, -B17, -B39, -B57, -Cw6 (the most fre-
quently observed), -Cw7 and class II HLA namely -
DR4,  DR7 (the most frequently encountered), -DR55
[4,5,16-19]. HLA-Cw6 positive individuals suffer
more frequently from psoriasis than their HLA-Cw6
negative siblings. In 1985, Henseler and Christophers
distinguished two types of non-pustular psoriasis
namely type I, inheritant and developing before the
age of 40, presenting a more severe course than type II,
sporadic, developing after the age of 40 with compar-
atively milder course [20].
It is worth pointing out that in psoriatic patients
from different cohorts various linkages and associa-
tions have been discovered. This could result from
many confounding factors including ascertainment
bias, gene-environment interactions, low effect size of
individual genetic variation [21].
Up till now, many psoriatic susceptibility loci have
been identified including the major ones located on
chromosomes 6p, 17q, 4q and 1q, and called PSORS
1, 2, 3 and 4, respectively) and the minor ones dis-
covered on chromosomes 16q and 20p [2,22,23].
Research data identified at least 20 psoriasis suscepti-
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bility loci on 15 different chromosomes out of which
nine were confirmed by studies in various populations
(PSORS 1-9) [24].
Research data on susceptibility locus located on
chromosome 6p, called PSORS-1 points out at his
locus as the core risk haplotype [25]. Moreover,
PSORS1 is the only psoriasis susceptibility locus that
has been always identified in genome-wide scans
responsible for about 35-50% of genetic predisposition
to psoriasis development [21]. Of note, HLA-Cw6 and
nine other genes (CDSN, HCR, POU5F1, TCF 19,
HCG 27, PSORS-1C3, SPR1, SEEK1, STG) are locat-
ed within PSORS-1 region. Furthermore, a highly
polymorphic MICA gen was also discovered  on chro-
mosome 6, however still beyond PSORS-1 region
[26].  It was found that MICA*017 was significantly
more frequently observed in patients with psoriasis
vulgaris whereas MICA*002 in arthropatic psoriasis
[27]. 
Clinical studies aiming at biologicals involved in
psoriasis, including cytokines, their inhibitors, fusion
proteins, monoclonal antibodies directed against T
lymphocytes and other leukocytes, employment in
psoriasis focused on pathogenic issues on immunolog-
ical disturbances, which in  turn depend on ker-
atinocytes response to inflammatory stimuli. Of
importance, psoriatic keratinocytes continuously pro-
duce enormously wide spectrum of cytokines showing
distinct biological functions (TNFα, IL-1, IL-6, IL-7,
IL-8, IL-15, IL-18, IL-19, IL-20, IL-23) [71]. The
majority of cytokines have pleiotropic effects on dif-
ferent cells and tissues and mutual interactions
12 A. Pietrzak et al.
©Polish Histochemical et Cytochemical Society
Folia Histochem Cytobiol. 2008:46(1): 12 (11-21) 
doi: 10.2478/v10042-008-0002-y
Table 1. Combined data on psoriasis susceptibility loci (with permission from authors Jullien and Barker [24]).
ND - not determined
between them are most frequently described as
cytokine network.   
Generally, cytokines are divided into a Th1-type
and Th2-type. Psoriatic plaques demonstrate predomi-
nance of Th1-type cytokines such as IL-2 and IFN-γ
[72,73]. However, different research groups revealed
other cytokines involvement, which cannot be simply
classified as Th1, Th0 or Th2 type, in psoriasis devel-
opment  [74,75].
Furthermore, in psoriasis interactions between dif-
ferent genes have been demonstrated thus leading to
various cytokines release which can be regarded as tar-
get of future effective therapy.
The updated list of intereleukins involved in psori-
asis pathogenesis is presented in Table 2.
Interleukin-1
Structure. IL-1 consists of three functionally and
structurally related polypeptides: two agonists of IL-1
receptor (IL-1α and IL-1β) and one antagonist 
(IL-1Ra) [76]. IL-1α and IL-1β are glycoproteins syn-
thesized in a form of precursors with molecular weight
of 31 kDa without signal peptide, which are then splitted
to mature form of molecular weight of 17 kDa. IL-1α is
already active as a precursor, mainly intracelullary. Its
mature form can be released from a cell as a result of
proIL-1α to IL-1α splitting by calcium activated pro-
teases, called calpains. Biological activity of IL-1β
results from intracellular cysteine protease ICE split-
ting (interleukin 1β-converting enzyme) [76]. Humans
have got four forms of IL-1Ra gene product: one solu-
ble isoform (sIL-1Ra) including the signal peptide,
with molecular weight of 17 kDa, as well as three
intracellular isoforms (icIL-1Ra1, icIL-1Ra2 and icIL-
1Ra3) [77]. sIL-1Ra is secreted by different cells and
has different degree of glycosylation, thus different
molecular weight ranging from 22 to 25 kDa. Intracel-
lular isoforms arise as a result of different cutting and
folding of tRNA (icIL-1Ra1) or the alternative place of
initiation of gene translation (icIL-1Ra3). sIL-1Ra iso-
form brakes competitively bonding of IL-1 with recep-
tor on cell surface, however the role of the intracellu-
lar isoform remains unknown [77].
Receptor. Family of IL-1 receptors belongs to TLR
receptor superfamily (Toll-like  receptor). Genes coding
IL-1RI, IL-1RII, IL-18R and IL-18RAcP are in cluster
of 530 kb on chromosome 2q12, gene coding IL 3q28 -
1RAcP is situated on chromosome 3q28 [78].  Compo-
nents of IL-1 receptor family were identified in the last
years on the basis of genomic analysis of row newly rec-
ognized proteins, in majority with poorly defined func-
tion [48]. There are two receptors for IL-1: IL-1RI and
IL-1RII [78].  IL-1RI receptor is a protein of 80 kDa
molecular weight. It has higher affinity to IL-1 and IL-
1alfa than IL1-RII receptor. It exists on majority of cells
sensitive to IL-1, mainly lymphocytes T, fibroblasts,
keratinocytes, endothelial cells, hepatocytes. Binding of
the third protein namely IL-1RAcP (IL-1 receptor
accessory protein), also belonging to IL-1 receptor fam-
ily, necessary for triggering of cell signal. IL-1RII
receptor of 68 kDa molecular weight has higher affinity
to IL-1β than to IL-1α, also weak affinity to IL-1Ra. It
is mainly found on neutrophiles, monocytes,
macrophages, B lymphocytes, bone marrow cells. It
exists in a membrane bound and soluble form. Soluble
form of IL-1RII also binds with IL-1β precursor, block-
ing its enzymatic splitting and activation. 
Interleukin-2
Structure. Mature product of gene for IL-2 is a glyco-
protein with molecular weight of 15,420 kDa consist-
ing of 133 amino acids [49]. Its structure is composed
of four antiparallel amphipathic alfa helices with one
intrachain disulfide bond, located between residues 58
and 105. It is worth pointing out that secondary and
tertiary protein structures are required for biologic
activity of IL-2 whereas the carbohydrate components
are dispensable  [79,80]. 
Receptor. Surface receptor for IL-2 is composed of
three kinds of protein chains, which join together non-
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Table 2. List of interleukins involved in psoriasis pathogenesis
with corresponding genes. 
covalently to create different configurations of recep-
tor: chain alpha (CD25, Tac) with 55kDa molecular
weight, beta (CD122) - 70-75 kDa and chain gamma
(CD132, p56) - 64 kDa. Receptor consisting of a sin-
gle chain alpha has the lowest affinity to IL-2, does not
transduce signal and is located on some resting T lym-
phocytes. Receptor with modest affinity to IL-2 con-
sists of chains beta and gamma, is located on mono-
cytes and the majority of NK cells. Receptor alpha-
betagamma has the strongest affinity and is located on
activated T and B lymphocytes as well as on 10% of
NK cells. The number of receptors on activated T lym-
phocytes is 10 times higher than on activated B lym-
phocytes. Beta chain plays the most important role in
signal transmission to cell interior. Gamma chain is not
specific for IL-2R and receptors for IL-4, IL-7, IL-9
and IL-15 also are composed of this chain [81,82]. The
soluble form of IL-2 receptor (sIL-2R) is formed upon
enzymatic cut off of the extracellular part of alpha
chain. sIL-2R exerts an immunosuppressive action and
competes with IL-2 membrane receptor. sIL-2R is
detected in low levels in serum. sIL-2R level increases
in some neoplastic and autoimmune diseases, as well
as in graft rejection [82-84].
Interleukin-4
Structure. The molecular weight of this glycoprotein
is about 20 kDa [85,86]. Its structure is similar to IL-2
and IL-13 and presents a globular nature composed of
four short alfa helices [51].
Receptor. IL-4 acts through two types of cell surface
receptors - type I and type II. One of these receptor is
expressed on a wide range of cells enabling IL-4 to
exert its action on various cell types [51].  IL-4 recep-
tor complex is composed of α chain of  120-130 kDa
molecular weight (800 amino acids) and γ chain
CD132/common γ chain). The latter is also encoun-
tered in receptors for the following cytokines: IL-2,
IL-7, IL-9, IL-15 and most probably IL-13 [87-90]. 
γ chain enhances affinity of α chain to IL-4. IL-4R α
chain is postulated to be also a component of IL-13
receptor [87,91]. Antibodies of  IL-4R α chain inhibit
IL-13 binding with its receptor (IL-13R) and thus their
function [91,92].
Interleukin-6 and interleukin-11 
Structure. IL-6 and IL-11 belong to a larger cytokine
family, sharing a four alpha helix kundle structure,
comprising also LIF, CNTF, OSM and CT-1 [93,94].
IL-6 is a glycoprotein of 21-28 kDa molecular weight
and consists of 184 amino acids [54]. IL-11 precursor
protein consists of 199 amino acids and molecular
weight of 23 kDa [56]. Although IL-11 belongs to the
same family as IL-6, no similarities are observed in
amino acids sequence and in cDNA between these
cytokines [56,95,96]. 
Receptor. IL-6, vIL-6, IL-11, LIF, OSM, CNTF, CT-1
and NNT-1/BSF-3 are also known as gp130 cytokines
because they all share gp130 subunit. This subunit
serves as a common transducer, by which Janus kinas-
es (Jaks) and transcription factors of the STAT (signal
transducers and activators of transcription) family are
activated. Moreover, IL-6, IL-11, OSM and CNTF also
share IL-11 specific α-receptors (IL-11Rα) [97]. IL-11
effects depend on IL-11Rα activity, responsible for
multimeric signal transduction including gp130 sub-
unit. Two isoforms of the human IL-11R α-chain,
which differ in their C-terminus domains, have been
identified and cloned. One isoform has a cytoplasmic
domain and the latter lacks the entire cytoplasmic
domain [98]. 
Interleukin-7
Structure. IL-7 is a single-chain glycoprotein and con-
sists of six cysteine residues. Both human and mouse
proteins contain three disulfide bonds which are essen-
tial for the biological activity of this cytokine. The
molecular weight of IL-7 is 25 kDa [99]. 
Receptor. The IL-7 receptor consists of a complex of
the IL-7Rα chain and the γc chain [100]. Both chains
are required for the biological activity of IL-7, which
was demonstrated in IL-7Rα-,  γc- and IL-7-deficient
mice. 
Interleukin-8
Structure. There are four types of differently
processed forms consisting of 69, 72, 77 and 79 amino
acids. IL-8 is formed as a precursor protein composed
of 99 amino acids. Most frequently it is a monocyte-
derived peptide (72 amino acids). Activated epithelial
cells produce a peptide which is 5 amino acids longer
[56]. The molecular weight of IL-8 is  8-10 kDa [56]. 
Receptor. There are two receptors: IL-8 RA and IL-8
RB, expressed on neutrophils, neutrophil-like cells,
monocytes, subpopulation of CD8+ T cells and CD
56+ natural killer cells. Additionally, the existence of
IL-8 multi-specific receptor (CK) was confirmed and
demonstrated on human erythrocytes. CK receptor was
demonstrated to be a blood group antigen in the Duffy
system  [101]. Because of its ability to bind IL-8, this
receptor regulates IL-8 level in serum. However, bio-
logical effects and stimulation pathways of the CK
receptor situated on erythrocytes are still not clearly
elucidated.
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Interleukin-10
Structure. IL-10 belongs to the family of long-chain
cytokines, which also encompasses IFN-α/β and IFN-
γ. Biologically active IL-10 is a homodimer  [102]
with  molecular weight of 37 kDa. Each monomer is
composed of 160 amino acids with a molecular weight
of 18.5 kDa. It is of interest that human IL-10 shares
80% homology with its murine counterpart. Literature
data point out at three viral IL-10 homologs namely
Epstein-Barr virus (BCRF1) [103,104], herpesvirus
type 2 [105], and orf virus [106]. X-ray crystal struc-
ture analysis revealed structures of human IL-10
[107,108]. 
Receptor. IL-10 receptors (IL-10R) are found on nor-
mal keratinocytes. They are composed of two different
chains: α and β (CRFB4) [109], which belongs to class
II-cytokine receptor family. The IL-10R β chain seems
to be essential for IL-10-mediated activity, because
characteristic STAT transcription factor activation pat-
tern for IL-10 signaling was observed only in cells
expressing both chains [109]. 
Interleukin-12
Structure. IL-12 consists of a disulfide heterodimer of
40 kDa (p40) and 35 kDa (p35) subunits [110].  The
peptide sequences of p35 and p40 are similar to  IL-6
and the soluble form of its receptor, suggesting that IL-
12 acts on target cells in a manner similar to the com-
plex of IL-6 and soluble IL-6R  [111]. There are also
many similarities between Il-12 and Il-23 [111].
Receptor. The functional high-affinity IL-12R com-
prises IL-12Rβ1 [112] and IL-12Rβ2 subunits [113].
IL-12 p40 binds primarily the IL-12Rβ1 subunit,
whereas IL-12 p35 appears to interact mostly with the
IL-12Rβ2 chain [113]. Although monometric p40 is
secreted in larger quantities than p70 heterodimer, only
the latter is biologically active [114]. This heterodimer
is produced after co-expression of both the p40 and the
p35 genes in the same cell [115]. The homodimer
binds with a much lower affinity than the heterodimer
and therefore acts as an antagonist only at much high-
er concentrations [116]. 
Interleukin-15
Structure. IL-15 is a glycoprotein with molecular
weight of 14-15 kDa. Its active form consists of 114
amino acids [117,118]. It is a member of 4 alpha helix
bundle family of cytokines.
Receptor. IL-15 type 1 receptor is found on T lympho-
cytes and NK cells. It consists of three subunits. Two
of them - β chain (protein p75) and γ chain (protein
p64) are components of IL-2 receptor [118, 119]. The
third element is a special α chain for IL-15 receptor
[120]. The second type of IL-15 receptor is located on
mast cells and probably it does not share the same ele-
ments with IL-2 receptor. Second type of receptor,
which is activated by IL-15 in mast cell proliferation,
is characterized by a new subunit initially defined as
IL-15RX  [121], and now described as an isoform of
IL-15R α chain [122].
Interleukin-17 
Interleukin-17 (IL-17) is a first member of a new
cytokine family. Of note, up till now it has been dis-
covered only in six species. Whereas, IL-17 is pro-
duced mainly by activated CD4+ and CD8+ T lym-
phocytes, its receptor can be found ubiquitously in the
organisms   [123].
Structure. Human IL-17 is a protein composed of 155
amino acids and shares about 75% homology at the
nucleotide level and 72% at the amino acid level with
the thirteenth open reading frame of the T lym-
photropic Herpesvirus saimiri (HVS13) [123,124]. IL-
17A structure sequence does not resemble any other
cytokine or mammalian protein [125]. That is why the
IL-17 cytokine family seems to represent a distinct lig-
and-receptor signaling system.
Receptor. As opposed to a relatively restricted expres-
sion of IL-17, IL-17 receptor (IL-17R) are ubiquitous-
ly expressed in all types of cells and tissues
[65,125,126]. It appears, that protein structure of IL-
17R is unrelated to those of other cytokine receptor
families. The IL-17R chain contains at least seven N-
linked glycosylation sites and the molecular weight of
nascent IL-17R protein is approximately 112 kDa. IL-
17R mRNA was detected in epithelial cells, fibrob-
lasts, lymphocytes, myelomonocytic cells and marrow
stromal cells [127]. The IL-17R protein as found in
peripheral blood T lymphocytes and vascular endothe-
lial cells [65]. Recent studies have demonstrated other
forms of IL-17 receptors, subsequently called IL-
17RB-E. The above receptors, similarly to IL-17R, are
type I transmembrane proteins, but display significant
alternative splicing [65].
Interleukin-18 
Structure. IL-18 is produced as a 24-kD inactive pre-
cursor lacking a signal peptide (pro-IL-18) [128]. Pro-
IL-18 is cleaved after Asp35 by the endoprotease IL-
1ß-converting enzyme (ICE; caspase-1) to generate a
biologically active, mature 18-kD fragment [128] .  IL-
1ß and IL-18 are closely related. Both interleukins
have a similar three-dimensional structure [129]. 
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Receptor. Interleukin-18 and its receptor, IL-18R, are
structurally related to IL-1 and the IL-1R family. All
members of the IL-1R family are composed of two
chains: the binding chain (IL-1R related protein, IL-
18Rα) and the signaling chain (IL-1R accessory pro-
tein-like, IL-18Rβ) [128-132].
Interleukin-19
Structure. IL-19 is secreted as monomer. The crystal-
lized monomer has seven helices able to bind to its
two-chain receptor [133].  
Receptor. Three members of the IL-19 family (IL-19,
IL-20 and IL-24) act through the receptor originally
defined as the IL-20 receptor [134,135]. Interestingly,
IL-20 and IL-24 can also use an alternative receptor
and indeed, recent investigations have suggested, that
the IL-20 receptor, as originally defined, may be the
true IL-19 receptor [136-138]. IL-19 act through the
IL-20R(1 or alfa)/IL-20R(2 or beta) heterodimer
which have been involved in triggering abnormal ker-
atinocyte differentiation and proliferation [135]. IL-19
receptor binding results in a rapid activation of the
transcription factor STAT3 (signal transducers and
activators of transcription 3) [136, 37].
Interleukin-20
Structure. The entire coding sequence translated from
full-length IL-20 cDNA clone indicates, that IL-20 is a
member of the IL-10 family and it is mostly similar to
IL-19 (40% of sequence identity) [139]. Recombinant
human IL-20 produced in BHK (renal cells of new
born Syrian hamsters) and baculovirus cells is a
monomer [134]. The IL-20 mRNA contains motifs in
its 3’untranslated region, that are associated with insta-
bility.  IL-20 mRNA appears to be rare and short-lived.
The polypeptide sequence of IL-20 is similar (20-40%
identical) to that of IL-10 and four other mammalian
cytokines  [140]. In contrast to IL-10, which only has
four conserved cysteine residues in its mature protein
sequence, IL-20 contains six of them. However, Gln81
and Asn134 residues in IL-10, corresponding to Cys81
and Cys134 in IL-20, have a separation of 11.6Å. IL-
10, which forms an intercalating dimer contains
Asn116 in a potential flexible hinge region between
the core of one monomer and the helix contributed by
the other monomer [134]. Based on a structural analy-
sis, IL-20 is assumed to share a similar three-dimen-
sional structure [141].  
Receptor. Recombinant IL-20 protein stimulates a sig-
nal transduction pathway through STAT3 in a ker-
atinocyte cell line, demonstrating a direct action of
this ligand. IL-20 receptor is the same as for IL-19
and was identified as a heterodimer of two orphan
class II cytokine receptor subunits, which are both
expressed in the skin [134]. Binding of the IL-20 lig-
and depends on a connecting recombinant monomer
of IL-20 to IL-20RA/IL-20RB  heterodimer com-
plex. The ligand does not bind itself, in any
detectable way, with any subunit, which can point
that IL-20 does not built homodimer causing impos-
sible ligand-induced homodimerisation of 2 α sub-
units. It is rather unique, that IL-20RA, as well as IL-
20RB are required for binding the IL-20 ligand.
Each of three IL-20 receptor subunits (IL-20RA, IL-
20RB and IL-22RA) has an individual expression
pattern in tissues [142]. 
Interleukin-23
Structure. IL-23 is a heterodimer, sharing a p40 sub-
unit  with IL-12 [143], but containing a distinct p19
subunit. Thus a human antibody directed against p40
effectively blocks the action of both IL-12 and IL-23
[143]. Interestingly, IL-12 and IL-23 are both pro-
duced by activated (mature) dendritic cells (DCs) and
play a key role in promoting differentiation and prolif-
eration of type 1 cytokine-producing naive and memo-
ry T cells, respectively [144].
Receptor. IL-23 binds to IL-12R1, but not to IL-
12R2. This cytokine has a heterodimeric receptor,
which uses a novel second subunit, IL-23R, a mem-
ber of the hematopoietin receptor family  [145]. The
receptor complex for IL-12/IL-23 is expressed or
upregulated on natural killer (NK) and T cells, as
well as on cells of the myelomonocytic lineage
including DCs. The presence of IL-23R in
macrophages and dendritic cells suggests, that IL-23
acts in an autocrine manner [145-148]. 
Tumor Necrosis Factor
Structure. The overall structure of TNF is described as
a "β-jellyroll" in which eight antiparallel β-strands
form a sandwich 3D structure. TNF precursor is a 233
amino acid, 26 kDa transmembrane glycoprotein type
II, comprising cytoplasmic domain and extracellular
C-terminus. As a mature form, TNF is released as an
17 kDa extracellular precursor fragment, consisting of
157 amino acids, as a result of TACE family metallo-
proteinases activity (TNF-alpha converting enzyme).
Biologically active forms, both membrane and soluble
ones, are homotrimers consisting of 3 identical protein
chains of non-convalescent bindings [149,150]. 
Receptor. Two TNF cell receptors i.e. TNFRI (also
called TNF-R55, TNFRβ, p55, CD120a) of 55 kDa
molecular weight and TNFRII (TNF-R75, TNFRα,
16 A. Pietrzak et al.
©Polish Histochemical et Cytochemical Society
Folia Histochem Cytobiol. 2008:46(1): 16 (11-21) 
doi: 10.2478/v10042-008-0002-y
p75, CD120b) of 75 kDa molecular weight can be
demonstrated. There are transmembrane  glycopro-
teins of different degree of glycosylation, molecular
weight, affinity and type of signal transduction.
TNFRI seems to be responsible for the majority of
TNF activity. However, TNFRII exerts a stronger
affinity to transmembrane pro-TNF [149,151]. TNFRI
and TNFRII are present on all cell types except for
erythrocytes. TNFRI expression is constitutive in most
cell types, whereas expression of TNFRII appears to
be inducible [150]. Soluble forms of both TNF recep-
tors -TNFRI and TNFRII are encountered in the blood.
The above forms are formed through proteolysis of
extracellular fragment, like the mature TNF. By bind-
ing TNF, soluble receptors exert an inhibitory or mod-
ulatory effect on TNF itself. On the other hand, how-
ever, they block dissociation of the active homotrimer
to  biologically inactive monomers thus prolonging
TNF activity  [149,152]. Both receptors, apart from
TNF, bind to  LT-  and one of LT- β (LT-α2β1). TNF
receptors are discovered on all nuclear mammal cells
and their number does not correlate with response to
TNF. IL-1, IL2, IFN-γ and TNF itself enhance the
expression of TNF receptors. Stimulation of TNF
receptors leads to protein kinases A and C activation
together with  NF-AT, NF-κB and AP-1 transcription
factors [151,153,154].
Interferon-γ
Interferons form a separate groups of proteins pro-
duced by numerous cells as a result of viral infection
or antigen stimulation [56,155].
Structure. IFN-γ is the only type II interferon, classi-
fied to this group because of its unique amino acid
sequence. IFN-γ in its biologically active form is a
34kDa homodimer stabilized by non-covalent forces.
The peptide is heterogenous in size and charge, due to
enzymatic trimming of the C-terminus and to variation
in degree of glycosylation. This heterogeneity seems
to be unimportant for biological activity on cells but
might well influence the dynamics of tissue distribu-
tion [1,156].
Receptor. Receptors for IFN-γ are located on the sur-
face of most of the cells of the body, so that many
organs and systems are sensitive to IFN-γ action.
Expression of IFN-γ receptor differ from cell to cell.
The highest expression of receptors is observed on T-
and B-lymphocytes, NK cells, monocytes,
macrophages, fibroblasts, neutrophils, endothelial and
smooth muscle cells. The receptor for IFN-γ is com-
posed of two structurally homologous polypeptides -
IFN-γ-Ra and IFN-γ-Rb. The signal transduction is
mediated by Jak1, Jak2 and STAT1a [156,157].
Conclusions and summing-up 
Since mid of the twenties century, dynamic develop-
ment on cytokine knowledge allowed not only to elu-
cidate mechanism of traditional anti-psoriatic treat-
ments but create the basis for elaboration of new effec-
tive biologicals. Fairly recently  first cytokine antago-
nists were registered for the treatment of autoimmuno-
logical inflammatory diseases, including skin and
arthropatic psoriasis, demonstrating much higher effi-
cacy than traditional therapies [150,155,158-160].
When thinking about biologicals employment,
detailed knowledge on genes and receptors of
cytokines and their structure is of importance for pso-
riasis. Data on this subject allow to understand treat-
ment f8ilures observed during many anti-cytokine
therapies as for example when anti-IL-8 is used.
Despite many theoretical aspects pointing out at anti-
IL-8 as a very effective anti-psoriatic component, this
anti-cytokine effects observed in practice were totally
disappointing. This lack of efficacy could at least be
partly explained by the presence of additional IL-8
receptors on erythrocytes. On the other hand, further,
still not fully elucidated,  interactions of cytokine net-
work could be to blame. This is why a single cytokine
introduction to anti-psoriatic treatment could at first
lead to clinical improvement, expressed as decrease in
PASI score (Psoriasis Area and Severity Index). How-
ever later usually a quick relapse of psoriasis follows. 
Literature data report both most spectacular suc-
cesses and disappointments of anti-cytokine treat-
ments in selected diseases, as for example in septic
shock [76]. Specially, the latter suggest the necessity
of more advanced therapeutic strategies implementa-
tion taking into account considerable diversity of sig-
nal transduction and mutual interactions between dif-
ferent cytokines and their receptors. It is of importance
that cytokine expression alters with the disease pro-
gression. However, up till now, only single cytokines
at a time are used in therapy.  There are no schemes of
combined anti-cytokine treatment taking into account
multi-cytokine approach. Multi-drug schemes of dif-
ferent anti-cytokine treatment, administered at differ-
ent stages of the disease should be elaborated in the
near future. 
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